Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611687 | 0.91 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5912624 | 0.83 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL6043079 | 0.81 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL9567 | 0.80 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2910471 | 0.80 | CA2 (0.50) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8239757 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL13747729 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL3654737 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL8343658 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5423307 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | claimed |
| JP-2007521278-A | — | — | 2007-08-02 | — | — | JP | claimed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | claimed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | CA2 4594/4885CA12 4860/4885CA1 4684/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | CA2 251/4885CA12 511/4885CA1 32/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | CA2 4553/4885CA12 4708/4885CA1 4869/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | CA2 4531/4885CA12 3846/4885CA1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.